{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:15:47Z","timestamp":1787498147200,"version":"build-2736575974"},"reference-count":16,"publisher":"Tohoku University Medical Press","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2022]]},"DOI":"10.1620\/tjem.2022.j074","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T18:22:48Z","timestamp":1661970168000},"page":"219-223","source":"Crossref","is-referenced-by-count":18,"title":["Telitacicept for Recalcitrant Cutaneous Manifestations of Systemic Lupus Erythematosus: A Case Report and Review of the Literature"],"prefix":"10.1620","volume":"258","author":[{"given":"Xinyue","family":"Ma","sequence":"first","affiliation":[{"name":"West China School of Medicine, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, West China Hospital, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, West China Hospital, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, West China Hospital, Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Brunner, H.I., Abud-Mendoza, C., Viola, D.O., Calvo Penades, I., Levy, D., Anton, J., Calderon, J.E., Chasnyk, V.G., Ferrandiz, M.A., Keltsev, V., Paz Gastanaga, M.E., Shishov, M., Boteanu, A.L., Henrickson, M., Bass, D.,  et al. (2020)  Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial.  <i>Ann. Rheum. Dis.<\/i>, 79, 1340-1348.","DOI":"10.1136\/annrheumdis-2020-217101"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Dall\u2019Era, M., Chakravarty, E., Wallace, D., Genovese, M., Weisman, M., Kavanaugh, A., Kalunian, K., Dhar, P., Vincent, E., Pena-Rossi, C. &amp; Wofsy, D. (2007)  Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.  <i>Arthritis Rheum.<\/i>, 56, 4142-4150.","DOI":"10.1002\/art.23047"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Dhillon, S. (2021)  Telitacicept: first approval.  <i>Drugs<\/i>, 81, 1671-1675.","DOI":"10.1007\/s40265-021-01591-1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Durcan, L., O\u2019Dwyer, T. &amp; Petri, M. (2019)  Management strategies and future directions for systemic lupus erythematosus in adults.  <i>Lancet<\/i>, 393, 2332-2343.","DOI":"10.1016\/S0140-6736(19)30237-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J.N., Cervera, R., Doria, A., Gordon, C., Govoni, M., Houssiau, F., Jayne, D., Kouloumas, M., Kuhn, A., Larsen, J.L.,  et al. (2019)  2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.  <i>Ann. Rheum. Dis.<\/i>, 78, 736-745.","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Nebro, A., de la Fuente, J.L., Carreno, L., Izquierdo, M.G., Tomero, E., Rua-Figueroa, I., Hernandez-Cruz, B.E., Narvaez, J., Ucar, E., Olive, A., Zea, A., Fernandez-Castro, M., Raya-Alvarez, E., Pego-Reigosa, J.M., Freire, M.,  et al. (2012)  Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study.  <i>Lupus<\/i>, 21, 1063-1076.","DOI":"10.1177\/0961203312446627"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Isenberg, D.A., Petri, M., Kalunian, K., Tanaka, Y., Urowitz, M.B., Hoffman, R.W., Morgan-Cox, M., Iikuni, N., Silk, M. &amp; Wallace, D.J. (2016)  Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.  <i>Ann. Rheum. Dis.<\/i>, 75, 323-331.","DOI":"10.1136\/annrheumdis-2015-207653"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Manzi, S., Sanchez-Guerrero, J., Merrill, J.T., Furie, R., Gladman, D., Navarra, S.V., Ginzler, E.M., D\u2019Cruz, D.P., Doria, A., Cooper, S., Zhong, Z.J., Hough, D.,  Freimuth, W. &amp; Petri, M.A.; BLISS-52 and BLISS-76 Study Groups (2012)  Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.  <i>Ann. Rheum. Dis.<\/i>, 71, 1833-1838.","DOI":"10.1136\/annrheumdis-2011-200831"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Merrill, J.T., Shanahan, W.R., Scheinberg, M., Kalunian, K.C., Wofsy, D. &amp; Martin, R.S. (2018)  Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.  <i>Ann. Rheum. Dis.<\/i>, 77, 883-889.","DOI":"10.1136\/annrheumdis-2018-213032"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Parodis, I., Gomez, A., Frodlund, M., Jonsen, A., Zickert, A., Sjowall, C., Bengtsson, A.A. &amp; Gunnarsson, I. (2018)  Smoking reduces the efficacy of belimumab in mucocutaneous lupus.  <i>Expert Opin. Biol. Ther.<\/i>, 18, 911-920.","DOI":"10.1080\/14712598.2018.1494719"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Salle, R., Chasset, F., Kottler, D., Picard-Dahan, C., Jannic, A., Mekki, N., De Risi-Pugliese, T., Monfort, J.B., Barbaud, A., Frances, C. &amp; Descamps, V. (2020)  Belimumab for refractory manifestations of cutaneous lupus: a multicenter, retrospective observational study of 16 patients.  <i>J. Am. Acad. Dermatol.<\/i>, 83, 1816-1819.","DOI":"10.1016\/j.jaad.2020.05.058"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Stohl, W., Schwarting, A., Okada, M., Scheinberg, M., Doria, A., Hammer, A.E., Kleoudis, C., Groark, J., Bass, D., Fox, N.L., Roth, D. &amp; Gordon, D. (2017)  Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study.  <i>Arthritis Rheumatol.<\/i>, 69, 1016-1027.","DOI":"10.1002\/art.40049"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Torrente-Segarra, V., Peramiquel, L. &amp; Bonet, M. (2021)  Belimumab in subacute cutaneous lupus erythematosus.  <i>Lupus<\/i>, 30, 2017-2018.","DOI":"10.1177\/09612033211033989"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Vashisht, P., Borghoff, K., O\u2019Dell, J.R. &amp; Hearth-Holmes, M. (2017)  Belimumab for the treatment of recalcitrant cutaneous lupus.  <i>Lupus<\/i>, 26, 857-864.","DOI":"10.1177\/0961203316682097"},{"key":"15","unstructured":"Wu, D., Li, J., Xu, D., Wang, W., Li, L., Fang, J. &amp; Zhang, F. (2019)  A human recombinant fusion protein targeting B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL), telitacicept (RC18), in systemic lupus erythematosus (SLE): results of a phase 2b study.  <i>Arthritis Rheumatol.<\/i>, 71 (suppl 10)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"Zhang, F., Bae, S.C., Bass, D., Chu, M., Egginton, S., Gordon, D., Roth, D.A., Zheng, J. &amp; Tanaka, Y. (2018)  A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.  <i>Ann. Rheum. Dis.<\/i>, 77, 355-363.","DOI":"10.1136\/annrheumdis-2017-211631"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/258\/3\/258_2022.J074\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:57:52Z","timestamp":1667005072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/258\/3\/258_2022.J074\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.2022.j074","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"2022.J074"}}